PriceTargets.com logo

Aptose Biosciences - APTO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.80
  • Forecasted Upside: 1,509.76%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.23 As of 04/19/2024 01:00 AM ET
▼ -0.04 (-3.15%)

This chart shows the closing price for APTO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aptose Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APTO

Analyst Price Target is $19.80
▲ +1,509.76% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Aptose Biosciences in the last 3 months. The average price target is $19.80, with a high forecast of $38.00 and a low forecast of $5.00. The average price target represents a 1,509.76% upside from the last price of $1.23.

This chart shows the closing price for APTO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Aptose Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$5.00Low
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$23.00Low
2/1/2024Piper SandlerLower TargetOverweight ➝ Overweight$12.00 ➝ $5.00Low
11/10/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$23.00 ➝ $18.00Low
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$38.00Low
8/11/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$40.00 ➝ $23.00Low
8/11/2023Piper SandlerLower TargetOverweight ➝ Overweight$37.00 ➝ $12.00Low
8/11/2023HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $23.00Low
8/11/2023OppenheimerLower TargetOutperform ➝ Outperform$50.00 ➝ $15.00Low
6/12/2023Cantor FitzgeraldBoost Target$6.00 ➝ $38.00Low
6/12/2023OppenheimerBoost Target$9.00 ➝ $50.00Low
6/7/2023Royal Bank of CanadaLower Target$75.00 ➝ $40.00Low
6/7/2023Piper SandlerLower Target$45.00 ➝ $37.00Low
3/27/2023Canaccord Genuity GroupLower TargetBuy$195.00 ➝ $120.00Low
3/24/2023Royal Bank of CanadaReiterated RatingOutperform$75.00Low
11/2/2022Royal Bank of CanadaLower TargetOutperform$90.00 ➝ $75.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
8/3/2022Cantor FitzgeraldLower Target$150.00 ➝ $90.00Low
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/23/2022HC WainwrightReiterated RatingBuyHigh
12/21/2021HC WainwrightLower TargetBuy$210.00 ➝ $180.00Low
12/14/2021Alliance Global PartnersLower TargetBuy ➝ Buy$180.00 ➝ $120.00High
11/17/2021Cantor FitzgeraldReiterated RatingOverweightMedium
11/12/2021HC WainwrightBoost TargetBuy$135.00 ➝ $210.00High
7/5/2021Piper SandlerLower TargetOverweight$180.00 ➝ $105.00Low
3/24/2021OppenheimerBoost TargetOutperform$120.00 ➝ $135.00High
2/22/2021JonestradingInitiated CoverageBuy$210.00High
10/19/2020Cantor FitzgeraldInitiated CoverageOverweight$150.00High
9/22/2020Alliance Global PartnersInitiated CoverageBuy$180.00High
6/23/2020Piper SandlerReiterated RatingOverweight$150.00High
6/14/2020OppenheimerInitiated CoverageBuy$135.00High
6/12/2020Maxim GroupInitiated CoverageBuy$240.00High
6/12/2020HC WainwrightReiterated RatingBuy$135.00Medium
4/27/2020HC WainwrightReiterated RatingBuy$135.00Medium
2/20/2020Maxim GroupInitiated CoverageBuy$240.00High
2/6/2020HC WainwrightBoost TargetBuy$90.00 ➝ $135.00Low
1/9/2020Piper SandlerInitiated CoverageOverweight$150.00High
8/7/2019HC WainwrightLower TargetBuy$127.50 ➝ $90.00Low
5/23/2019Roth CapitalReiterated RatingBuyHigh
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Aptose Biosciences logo
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $1.23
Low: $1.23
High: $1.29

50 Day Range

MA: $1.62
Low: $1.23
High: $2.06

52 Week Range

Now: $1.23
Low: $1.20
High: $8.70

Volume

36,438 shs

Average Volume

89,259 shs

Market Capitalization

$19.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptose Biosciences?

The following equities research analysts have issued reports on Aptose Biosciences in the last year: Cantor Fitzgerald, HC Wainwright, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for APTO.

What is the current price target for Aptose Biosciences?

5 Wall Street analysts have set twelve-month price targets for Aptose Biosciences in the last year. Their average twelve-month price target is $19.80, suggesting a possible upside of 1,509.8%. Cantor Fitzgerald has the highest price target set, predicting APTO will reach $38.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $5.00 for Aptose Biosciences in the next year.
View the latest price targets for APTO.

What is the current consensus analyst rating for Aptose Biosciences?

Aptose Biosciences currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APTO will outperform the market and that investors should add to their positions of Aptose Biosciences.
View the latest ratings for APTO.

What other companies compete with Aptose Biosciences?

Other companies that are similar to Aptose Biosciences include Surrozen, Evaxion Biotech A/S, PharmaCyte Biotech, AIM ImmunoTech and Inhibikase Therapeutics. Learn More about companies similar to Aptose Biosciences.

How do I contact Aptose Biosciences' investor relations team?

Aptose Biosciences' physical mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company's listed phone number is 858-926-2730 and its investor relations email address is [email protected]. The official website for Aptose Biosciences is www.aptose.com. Learn More about contacing Aptose Biosciences investor relations.